Insider Notice: Hanlin Gao Plans Sale of 943 FLGT Shares via Morgan Stanley

Rhea-AI Filing Summary

Fulgent Genetics insider sale notice: This Form 144 reports that Hanlin Gao plans to sell 943 shares of Fulgent Genetics common stock through Morgan Stanley Smith Barney (New York) with an aggregate market value of $20,260.11 and an approximate sale date of 08/27/2025. The filing shows 30,609,044 shares outstanding for the issuer. The shares to be sold were acquired on 02/26/2024 as restricted stock that vested (21,146 shares acquired as equity compensation). The notice lists four prior sales by Hanlin Gao between 05/27/2025 and 08/25/2025, totaling 2,341 shares with gross proceeds reported for each transaction. The filer certifies no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale of vested restricted shares; size is small versus total outstanding shares and appears non-material.

The filing documents a proposed sale of 943 shares through a broker and shows prior small dispositions by the same insider. The shares were acquired as restricted stock that vested, indicating these are compensation-related holdings being liquidated. The aggregated market value reported is $20,260.11. Given the modest absolute size relative to the issuer's reported outstanding shares, this notice is likely a routine liquidity event rather than a material change to company capitalization.

Corporate Governance Expert

TL;DR: Insider selling vested equity under Rule 144; form includes the required representation about material information.

The filer used Rule 144 disclosure to notify a brokered sale of common stock and affirmed there is no undisclosed material adverse information. The securities were granted as equity compensation and vested on the acquisition date shown, which supports a compliance-focused sale rather than an opportunistic trade. Documentation of prior small sales over recent months suggests a pattern of routine disposals consistent with liquidity needs or planned sales under compliance procedures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	943	20260.11	30609044	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/26/2024	Restricted stock vest	Fulgent Genetics, Inc.			21146	02/26/2024	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	383	7880.32
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	656	13459.08
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	06/02/2025	754	15299.28
Hanlin Gao C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/25/2025	548	11782.85

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who is selling shares according to the Form 144 for FLGT?

The seller named in the filing is Hanlin Gao (c/o Fulgent Genetics, Inc.).

How many Fulgent Genetics (FLGT) shares are proposed for sale and when?

The Form 144 reports 943 shares proposed for sale with an approximate sale date of 08/27/2025.

Through which broker will the FLGT shares be sold?

The filing lists Morgan Stanley Smith Barney LLC (1 New York Plaza, 38th FL, New York, NY) as the broker.

When and how were the shares to be sold acquired?

The 943 shares were acquired on 02/26/2024 as restricted stock that vested and were issued as equity compensation for services rendered.

Has the filer sold FLGT shares recently?

Yes. The filing lists four prior sales by Hanlin Gao on 05/27/2025, 06/02/2025, and 08/25/2025 totaling 2,341 shares with gross proceeds reported for each sale.

What representation does the filer make about material information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.